查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2012592

癌症诊断市场：按技术、癌症类型和最终用户划分－2026年至2032年全球市场预测

Cancer Diagnostics Market by Technology, Cancer Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025年癌症诊断市值为370.2亿美元，预计到2026年将成长至411.5亿美元，复合年增长率为12.26%，到2032年将达到832.3亿美元。

主要市场统计数据
基准年 2025 370.2亿美元
预计年份：2026年 411.5亿美元
预测年份 2032 832.3亿美元
复合年增长率 (%) 12.26%

对受技术融合、治疗过程变革和监管变化驱动的肿瘤诊断格局的紧迫而全面的展望。

肿瘤诊断领域正经历快速发展，主要得益于技术融合、监管改革和临床路径的转变。分子诊断平台、高解析度成像和先进细胞分析技术的进步，大大提升了临床医生和研究人员检测、分型和监测癌症的能力，其精准度达到了前所未有的水平。同时，随着诊断决策越来越贴近患者，医疗服务模式也在发生变化，多学科团队需要整合来自组织病理学、基因组定序和影像衍生生物标记的资讯。

技术民主化、多模态资料整合和监管重组如何共同重新定义肿瘤学的诊断路径和商业性需求。

肿瘤诊断格局正经历一系列相互关联的变革，这些变革共同重塑临床实践和商业性机会。科技的普及化是其中的核心主题。检测流程的简化和自动化，以及透过数位化介面实现结果解读的标准化，正将曾经局限于专业实验室的平台推广至常规医院检查室和门诊机构。这种普及加速了分子诊断和先进免疫检测在社区医疗机构的应用，从而实现更早期的疾病检测和更精细的疾病分层。

评估 2025 年美国关税措施对供应链、采购成本和诊断技术策略部署的多方面影响。

美国2025年宣布或实施的关税调整将对肿瘤诊断领域的企业产生复杂的上下游影响。最直接的影响是，进口设备和试剂关税的提高可能会推高成像设备、流式细胞仪和定序仪等昂贵设备以及国内尚无成熟替代产品的专用耗材的最终采购成本。这些成本压力可能会挤压依赖全球供应链的製造商的利润空间，并增加进口设备或依赖外国试剂的检查室和医疗系统的部署成本和单次检测成本。

基于细分的详细洞察，绘製特定技术的价值链、特定癌症的诊断需求以及多样化的最终用户采用路径，从而实现策略优先排序。

精细化的细分观点揭示了每种技术平台、癌症类型和终端用户管道的不同机会和风险特征，从而为产品定位和商业化提供了清晰的策略方向。在技​​术领域，流式细胞技术分为细胞分选和多参数流式细胞技术两大类，各自拥有独特的临床和研究应用。细胞分选对于转化研究和自体细胞治疗仍然至关重要，而多参数流式细胞技术则在血液学诊断中推进免疫表型分析和微量残存疾病评估。影像技术包括电脑断层扫描（CT）、磁振造影（MRI）、超音波，每种方式在诊断、分期和治疗监测方面都具有独特的价值。 PET 和 MRI 尤其重要，因为其代谢和功能性观察有助于标靶治疗的选择，而 CT 和超音波继续在急诊和门诊环境中提供广泛的应用和快速影像。

世界各地不同的报销制度、法规结构和医疗保健基础设施如何影响实施重点和商业策略？

区域趋势对美洲、欧洲、中东和非洲以及亚太地区的技术采纳、报销途径和伙伴关係模式有显着影响，每个地区都拥有其独特的医疗保健结构和创新生态系统。在美洲，成熟的私营和公共保险公司与领先的学术研究中心和强大的商业诊断产业并存。这种环境有利于高价值分子检测和先进影像技术的快速应用，同时也需要强有力的证据支持项目来确保报销和处方药资格。此外，美洲的采购惯例倾向于签订综合性长期服务合同，这对于能够提供全面售后服务和耗材供应网络的供应商而言具有优势。

平台的规模、测试方法的专业性、服务的经济性以及策略联盟塑造的竞争动态——所有这些因素共同决定了商业性韧性和成长轨迹。

肿瘤诊断领域的竞争动态由大规模综合平台供应商、专业检测方法开发公司以及专注于特定临床应用的敏捷型新兴参与企业共同构成。成熟的仪器製造商利用其规模、广泛的服务网络和整合的耗材生态系统来维护现有基本客群，而专业公司则透过检测方法创新、软体驱动的分析以及与临床中心的策略合作来脱颖而出。在整个竞争格局中，差异化越来越依赖于展现临床效用、透过自动化简化检查室工作流程以及提供永续的服务和试剂供应链的能力。

领导企业为增强供应链韧性、证据产生和整合临床部署以实现永续成长而采取的优先策略行动。

产业领导企业应采取切实可行且优先排序的措施，将新兴趋势转化为可持续的竞争优势。首先，投资于供应链透明度和多元化，以减轻关税和贸易中断的影响。这包括探索替代供应商、评估区域合作生产和共同生产的机会，以及实施平衡营运资本和供应连续性的库存策略。其次，制定蓝图，以产生能够证明关键适应症的临床效用和健康经济价值的证据。儘早投资于前瞻性研究和真实世界数据将加快支付方的参与，并促进报销谈判，尤其是在高成本分子检测和伴随诊断方面。

一个稳健的混合方法研究框架，结合了相关人员访谈、文献整合、定量映射和专家检验，以确保基于证据的见解。

本次高阶主管综合研究采用混合方法，旨在整合来自多个互补资讯来源的见解，并透过专家咨询检验这些见解。主要研究包括对医院、诊断检查室和研究机构的临床负责人、实验室主任和采购主管进行结构化访谈，并辅以对诊断设备製造商和技术供应商的高级管理人员的访谈。这些工作提供了有关应用驱动因素、采购限制以及影响报销决策的证据需求的定性背景资讯。

策略性问题整合：临床效用、供应链韧性和综合解决方案决定了肿瘤诊断的长期成功。

综合以上分析表明，肿瘤诊断生态系统正处于策略转折点，技术可能性、支付方期望和供应链现实在此交汇。对于那些能够将技术差异化转化为可证实的临床价值，同时在贸易和采购环境波动的情况下维持营运韧性的机构而言，存在着许多机会。多模态诊断和整合报告的发展趋势将越来越有利于那些提供互通解决方案并积极与临床相关人员合作，将诊断整合到诊疗路径中的供应商。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：癌症诊断市场：依技术划分

  • 流式细胞技术
    • 细胞分选
    • 多参数流式细胞技术
  • 影像
    • 电脑断层扫描
    • 磁振造影
    • 正子断层扫描
    • 超音波
  • 免疫组织化学
    • 显色方法
    • 萤光
  • 原位杂合反应
  • 分子诊断
    • 微阵列
    • PCR
    • 定序

第九章：以癌症类型分類的癌症诊断市场

  • 血癌
    • 白血病
    • 淋巴瘤
    • 多发性骨髓瘤
  • 固体癌
    • 乳癌
    • 结肠癌
    • 肺癌
    • 摄护腺癌

第十章 癌症诊断市场：依最终用户划分

  • 门诊治疗
  • 诊断检查室
  • 医院
  • 研究机构
    • 学术机构
    • 私人研究机构

第十一章 癌症诊断市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章 癌症诊断市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章 癌症诊断市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章：美国癌症诊断市场

第十五章：中国癌症诊断市场

第十六章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Canon Medical Systems Corporation
  • Danaher Corporation
  • Danaher Corporation
  • DiaSorin SpA
  • F. Hoffmann-La Roche Ltd
  • Fujifilm Corporation
  • GE HealthCare Technologies Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Myriad Genetics, Inc.
  • NeoGenomics Laboratories, Inc.
  • PerkinElmer, Inc.
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-436145BF8B0C

The Cancer Diagnostics Market was valued at USD 37.02 billion in 2025 and is projected to grow to USD 41.15 billion in 2026, with a CAGR of 12.26%, reaching USD 83.23 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 37.02 billion
Estimated Year [2026] USD 41.15 billion
Forecast Year [2032] USD 83.23 billion
CAGR (%) 12.26%

An urgent and comprehensive orientation to the evolving oncology diagnostics environment driven by technology convergence, care pathway transformation, and regulatory shifts

The oncology diagnostics landscape is experiencing a period of rapid evolution driven by technological convergence, regulatory recalibration, and shifting clinical pathways. Advances across molecular platforms, high-resolution imaging, and sophisticated cellular analytics are expanding the capabilities of clinicians and researchers to detect, subtype, and monitor cancer with unprecedented precision. At the same time, care delivery models are changing as diagnostic decision-making migrates closer to the patient, and as multidisciplinary teams demand integrated information flows that combine histopathology, genomic sequencing, and imaging-derived biomarkers.

Against this backdrop, market participants face a complex interplay of innovation opportunities and operational challenges. Diagnostic developers are competing on assay sensitivity and specificity, throughput, and cost of ownership, while health systems increasingly emphasize value-based outcomes and diagnostic efficiency. Regulatory expectations for companion diagnostics and next-generation sequencing workflows are maturing, and payers are reassessing reimbursement pathways for tests that promise improved treatment selection and reduced downstream costs. As a result, the competitive environment rewards organizations that can pair scientific rigor with pragmatic deployment strategies that address clinical workflows and reimbursement realities.

This executive summary synthesizes the most consequential trends reshaping cancer diagnostics, analyzes potential policy and tariff-driven disruptions, delineates segmentation-level insights across technology, cancer type, and end user, evaluates regional dynamics, and identifies strategic options for companies seeking to sharpen their competitive positioning. The subsequent sections provide a cohesive narrative designed to inform corporate strategy, investment decisions, and operational planning across stakeholder groups involved in oncology diagnostics and associated services.

How technological democratization, multimodal data integration, and regulatory realignment are jointly redefining diagnostic pathways and commercial imperatives in oncology

The diagnostic oncology landscape is being transformed by a set of interrelated shifts that together are redefining clinical practice and commercial opportunity. Technological democratization is a central theme: platforms once confined to specialized reference laboratories are moving into routine hospital laboratories and ambulatory settings as assay workflows are simplified, automation increases, and digital interfaces standardize results interpretation. This diffusion is accelerating the adoption of molecular diagnostics and advanced immunoassays in community settings, enabling earlier detection and more granular disease stratification.

Simultaneously, the integration of multimodal data streams is reshaping diagnostic outputs. Clinicians now expect reports that combine genomic findings with immunohistochemical patterns, spatial profiling, and cross-sectional imaging biomarkers, creating more actionable diagnostic narratives for precision therapy selection and longitudinal monitoring. This shift incentivizes cross-disciplinary collaboration between pathology, radiology, and molecular diagnostic teams, and it favors companies that can offer interoperable systems or curated data platforms that reduce friction in data synthesis.

Payer and regulatory environments are also influencing strategic direction. Payers are increasingly focused on demonstrable clinical utility and real-world outcomes, prompting diagnostic developers to invest in evidence-generation programs and outcomes studies. Regulators are adapting frameworks to address novel test modalities, companion diagnostics, and decentralized testing, which is accelerating the need for robust analytical validation and post-market surveillance. Finally, supply chain resilience and cost pressures are prompting manufacturing realignment and more selective procurement practices, encouraging vertical integration and strategic alliances focused on securing critical reagent supplies and instrument service networks.

Taken together, these transformative shifts create a landscape where technological innovation alone is insufficient; success requires interoperable solutions, evidence-driven adoption strategies, and operational resilience that collectively enable diagnostics to be both clinically impactful and commercially sustainable.

Assessing the multi-dimensional consequences of 2025 U.S. tariff measures on supply chains, procurement costs, and strategic deployment of diagnostic technologies

Tariff changes announced or implemented in 2025 in the United States present a complex set of upstream and downstream implications for companies operating in the diagnostic oncology space. At the most direct level, increased duties on imported instruments and reagents can raise landed costs for high-capital equipment such as imaging modalities, flow cytometers, and sequencers, as well as for specialized consumables that lack mature domestic manufacturing alternatives. These cost pressures can compress margins for manufacturers that rely on global supply chains and can increase acquisition and per-test costs for laboratories and health systems that import equipment or rely on foreign-produced reagents.

Beyond direct pricing effects, tariffs can precipitate strategic responses across the value chain. Manufacturers may accelerate regionalization of production, shift sourcing to tariff-exempt suppliers, or redesign products to incorporate components that are domestically available. Such adjustments can reduce exposure over time but may require capital investment, requalification of supply chains, and renegotiation of service contracts, each of which can introduce implementation risk and near-term cost volatility. Laboratories and hospitals may respond by modifying procurement cycles, consolidating purchasing, or entering into longer-term service and consumable agreements to stabilize unit costs, which could favor vendors with broad service footprints and flexible commercial terms.

Tariffs also materially affect the economics of decentralized testing adoption. If the incremental cost of portable or point-of-care devices rises due to duties on critical components, deployment decisions may favor centralized high-throughput models where economies of scale can partially neutralize tariff impacts. Conversely, tariffs that disproportionately affect specialized reagents could shift demand toward alternative diagnostic modalities with lower import exposure, potentially accelerating investment in domestically manufactured assays or in technologies that rely more on software and analytics than on high-cost consumables.

In addition, tariff-induced uncertainty has implications for clinical research and development. Sponsors conducting multi-site trials that require imported diagnostic kits may face higher trial costs and longer timelines for kit distribution and regulatory compliance. This could influence site selection and the timing of companion diagnostic rollouts. Finally, the cumulative impact of tariffs should be viewed through a strategic lens: in environments of sustained trade policy volatility, organizations that invest in supply chain transparency, diversified sourcing, and adaptive pricing strategies will be better positioned to maintain service levels and preserve market access in core clinical and commercial channels.

Deep segmentation-driven insights that map technology-specific value chains, cancer-type diagnostic needs, and varied end-user adoption pathways for strategic prioritization

A granular segmentation lens reveals differentiated opportunity and risk profiles across technological platforms, cancer types, and end-user channels, offering strategic clarity for product positioning and commercialization. Within technology, flow cytometry splits into cell sorting and multiparameter flow cytometry segments, each with distinct clinical and research applications; cell sorting remains essential for translational research and autologous cell therapies, while multiparameter flow cytometry drives immunophenotyping in hematological diagnostics and minimal residual disease assessment. Imaging technologies encompass computed tomography, magnetic resonance imaging, positron emission tomography, and ultrasound, with each modality contributing unique value to diagnosis, staging, and treatment monitoring; PET and MRI are particularly pivotal where metabolic and functional readouts inform targeted therapy selection, whereas CT and ultrasound continue to offer broad accessibility and rapid imaging endpoints in acute care and outpatient pathways.

Immunohistochemistry subdivisions between chromogenic and fluorescent approaches reflect a trade-off between established workflows and higher-plex spatial resolution, with chromogenic methods maintaining ubiquity in routine pathology while fluorescent assays enable multiplexed biomarker panels and spatial profiling. In situ hybridization remains critical for detecting gene rearrangements and copy number changes within tissue architecture, complementing molecular diagnostics that span microarray, PCR, and sequencing technologies. Within molecular diagnostics, microarray applications persist where broad gene expression profiling is needed, PCR maintains a central role for targeted mutation detection and minimal residual disease assays due to its sensitivity and turnaround speed, and sequencing delivers comprehensive genomic insights that increasingly underpin precision oncology decisions.

Cancer-type segmentation highlights divergent diagnostic needs between hematological malignancies and solid tumors. Hematological cancers, including leukemia, lymphoma, and multiple myeloma, rely heavily on flow cytometry, molecular assays, and bone marrow-focused workflows for diagnosis, disease classification, and therapy monitoring. Solid tumors, comprising breast, colorectal, lung, and prostate cancers among others, demand integrated pipelines that combine tissue-based immunohistochemistry, in situ hybridization, and sequencing to inform biomarker-driven treatment selection. Each cancer subtype presents unique specimen handling, assay sensitivity, and biomarker validation requirements that shape commercial strategies.

End-user segmentation across ambulatory care, diagnostic laboratories, hospitals, and research institutes influences adoption velocity and procurement complexity. Ambulatory settings prioritize point-of-care efficiency and rapid reporting, whereas diagnostic laboratories emphasize throughput, accreditation compliance, and cost per test. Hospitals must balance in-house capacity with referral networks, often favoring integrated vendor solutions with service and training bundles. Research institutes, including academic centers and private research centers, drive early adoption of novel platforms and provide critical evidence-generation partnerships, acting as both customers and collaborators in assay validation and clinical utility studies. Collectively, these segmentation dynamics underscore the need for differentiated value propositions tailored to clinical workflows, reimbursement environments, and the operational constraints of each end-user cohort.

How divergent reimbursement regimes, regulatory frameworks, and healthcare infrastructures across global regions shape adoption priorities and commercial strategies

Regional dynamics exert a strong influence on technology adoption, reimbursement pathways, and partnership models across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each exhibiting distinct healthcare structures and innovation ecosystems. In the Americas, mature private and public payers coexist with leading academic centers and a robust commercial diagnostics sector; this environment supports rapid uptake of high-value molecular tests and advanced imaging but also demands strong evidentiary programs to secure reimbursement and formulary positioning. Furthermore, procurement practices in the Americas often favor integrated service arrangements and long-term service contracts, which can advantage vendors that offer comprehensive post-sales support and consumable supply networks.

In Europe, Middle East & Africa, reimbursement systems are more heterogeneous and often more prescriptive about test reimbursement criteria, which can slow adoption of novel diagnostics without strong health economic data. Regulatory harmonization efforts in Europe promote cross-border collaboration, while pockets of innovation in the Middle East and Africa are driven by government-led investments in tertiary care and diagnostic infrastructure. Vendors operating in this region must navigate diverse national reimbursement frameworks and prioritize local evidence generation and partnerships with accredited laboratories to scale adoption.

Asia-Pacific presents a rapidly expanding opportunity space characterized by varied maturity across markets, from advanced economies with high adoption of sequencing and digital pathology to emerging markets where point-of-care diagnostics and cost-effective imaging are paramount. Government-led initiatives to strengthen cancer screening programs and investments in domestic manufacturing capacity are shaping procurement preferences and local partnerships. Across Asia-Pacific, considerations such as regulatory pathway clarity, localization of technical support, and pricing sensitivity play decisive roles in go-to-market strategies.

Taken together, these regional distinctions call for differentiated commercial playbooks that balance global platform consistency with localized evidence generation, regulatory navigation, and tailored service models. Strategic alliances with regional distributors, targeted clinical partnerships, and adaptive pricing strategies will be instrumental in translating product capabilities into sustainable clinical and commercial uptake across diverse health systems.

Competitive dynamics shaped by platform scale, assay specialization, service economics, and strategic alliances that together determine commercial resilience and growth trajectories

Competitive dynamics in diagnostic oncology are defined by a mix of large integrated platform providers, specialized assay developers, and agile newcomers focused on niche clinical applications. Established instrument manufacturers continue to leverage scale, broad service footprints, and integrated consumable ecosystems to defend installed bases, while specialist companies differentiate through assay innovation, software-enabled analytics, and strategic partnerships with clinical centers. Across the competitive landscape, differentiation increasingly hinges on the ability to demonstrate clinical utility, streamline laboratory workflows through automation, and provide durable service and reagent supply arrangements.

Partnerships and acquisitions remain central to capability expansion. Larger diagnostic firms frequently pursue bolt-on acquisitions to augment sequencing capacity, add multiplexed immunoassay capabilities, or incorporate digital pathology and AI-enabled interpretation tools. Meanwhile, smaller developers often seek co-development agreements with academic medical centers and contract research organizations to accelerate clinical validation and create reference datasets that support regulatory submissions and payer discussions. Strategic collaborations between instrument manufacturers and specialty reagent providers are also common, aligning product roadmaps to create bundled propositions that simplify procurement and ensure reagent availability.

Service economics and consumables revenue streams play a critical role in commercial viability. Vendors that combine robust field service networks with predictable consumable revenue models benefit from higher lifetime customer value and greater resilience against procurement cycle volatility. Software and informatics offerings further differentiate vendors by enabling data integration across modalities, facilitating longitudinal patient tracking, and supporting real-world evidence generation. Companies that invest in cloud-enabled platforms and interoperable data standards can unlock higher value by offering analytics-as-a-service and by simplifying multi-modal diagnostic workflows for clinical laboratories and health systems.

Overall, the competitive environment rewards organizations that combine scientific excellence with operational execution: those that can rapidly validate clinical utility, ensure uninterrupted reagent and service availability, and deliver interoperable diagnostic ecosystems will be best positioned to capture growing demand in precision oncology.

Prioritized strategic actions for diagnostics leaders to strengthen supply resilience, evidence-generation, and integrated clinical deployment for sustainable growth

Industry leaders should pursue a set of pragmatic, prioritized actions to convert emerging trends into durable competitive advantage. First, invest in supply chain transparency and diversification to reduce exposure to tariff- or trade-driven disruptions; this includes assessing alternative suppliers, evaluating regional manufacturing or co-manufacturing opportunities, and implementing inventory strategies that balance working capital with continuity of supply. Second, develop evidence-generation roadmaps that demonstrate clinical utility and health-economic value across key indications; early investment in prospective studies and real-world evidence will accelerate payer engagement and facilitate reimbursement discussions, particularly for high-cost molecular tests and companion diagnostics.

Third, prioritize product interoperability and integration with clinical workflows by adopting open standards and building partnerships with electronic health record and laboratory information system vendors. Simplifying integration reduces adoption friction in hospitals and reference laboratories and increases the stickiness of diagnostic solutions. Fourth, tailor commercial models to regional realities; deploy flexible pricing and contracting approaches that account for differing reimbursement environments and procurement cycles, and invest in regional service capabilities where uptime and consumable access are central to customer satisfaction.

Fifth, cultivate strategic partnerships with academic centers, clinical networks, and research institutes to accelerate validation, generate robust datasets, and co-create clinical pathways that embed diagnostics into standard care. These collaborations can also serve as early-warning systems for emerging clinical needs and regulatory trends. Finally, embed agility into R&D and commercialization processes by adopting modular development approaches, shortening iteration cycles, and aligning product development with evolving payer evidence requirements. Together, these actions balance risk mitigation with growth orientation and position organizations to scale responsibly in a dynamic oncology diagnostics market.

A robust mixed-methods research framework combining stakeholder interviews, literature synthesis, quantitative mapping, and expert validation to ensure evidence-based findings

The research underpinning this executive synthesis employed a mixed-methods approach designed to triangulate insights from multiple, complementary sources and to validate findings through expert consultation. Primary research included structured interviews with clinical leaders, laboratory directors, and procurement executives across hospitals, diagnostic laboratories, and research institutes, supplemented by interviews with senior executives from diagnostic manufacturing organizations and technology vendors. These engagements provided qualitative context on adoption drivers, procurement constraints, and the evidence needs that influence reimbursement decisions.

Secondary research encompassed a systematic review of peer-reviewed clinical literature, regulatory guidance documents, technical white papers, and public disclosures relating to diagnostic technologies, assay performance characteristics, and clinical utility studies. Where available, real-world datasets and registry analyses were assessed to contextualize diagnostic pathways and to identify patterns in assay utilization and clinical decision-making. Insights from these sources were synthesized to identify convergent themes and to cross-validate claims made in primary interviews.

Quantitative analyses included mapping of product portfolios against segmentation matrices, assessment of supply chain concentration for critical components, and scenario analysis to evaluate potential impacts of policy shifts such as tariff changes. Findings were stress-tested via expert panels comprising pathologists, molecular diagnostic scientists, radiologists, and health economics specialists to ensure clinical plausibility and to refine recommendations. Throughout the process, methodological rigor was maintained through transparent documentation of interview protocols, source attribution, and limitations, enabling readers to assess the strength of evidence behind key conclusions.

Synthesis of strategic imperatives showing that clinical utility, supply chain resilience, and integrated solutions determine long-term success in oncology diagnostics

The cumulative analysis points to a diagnostic oncology ecosystem at a strategic inflection point where technological potential, payer expectations, and supply chain realities intersect. Opportunities abound for organizations that can translate technological differentiation into demonstrable clinical value while ensuring operational resilience in the face of trade and procurement volatility. The trend toward multimodal diagnostics and integrated reporting will increasingly favor vendors that provide interoperable solutions and active collaboration with clinical stakeholders to embed diagnostics into care pathways.

At the same time, the landscape will reward disciplined evidence generation and adaptive commercial models. Tests and platforms that lack robust demonstration of clinical utility and cost-effectiveness will face adoption headwinds, particularly in markets with conservative reimbursement frameworks. Additionally, the capacity to manage supply chain complexity, whether through localization, diversified sourcing, or strategic partnerships, will be a deciding factor in sustaining market access and customer trust.

In sum, the organizations most likely to capture long-term value are those that align scientific innovation with pragmatic deployment strategies: they will invest in high-quality evidence, build resilient supply and service networks, and design interoperable, clinician-friendly solutions that reduce friction in real-world practice. These priorities will serve as the foundation for scalable growth in the evolving oncology diagnostics marketplace.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Diagnostics Market, by Technology

  • 8.1. Flow Cytometry
    • 8.1.1. Cell Sorting
    • 8.1.2. Multiparameter Flow Cytometry
  • 8.2. Imaging
    • 8.2.1. Computed Tomography
    • 8.2.2. Magnetic Resonance Imaging
    • 8.2.3. Positron Emission Tomography
    • 8.2.4. Ultrasound
  • 8.3. Immunohistochemistry
    • 8.3.1. Chromogenic
    • 8.3.2. Fluorescent
  • 8.4. In Situ Hybridization
  • 8.5. Molecular Diagnostics
    • 8.5.1. Microarray
    • 8.5.2. Pcr
    • 8.5.3. Sequencing

9. Cancer Diagnostics Market, by Cancer Type

  • 9.1. Hematological Cancers
    • 9.1.1. Leukemia
    • 9.1.2. Lymphoma
    • 9.1.3. Multiple Myeloma
  • 9.2. Solid Tumors
    • 9.2.1. Breast Cancer
    • 9.2.2. Colorectal Cancer
    • 9.2.3. Lung Cancer
    • 9.2.4. Prostate Cancer

10. Cancer Diagnostics Market, by End User

  • 10.1. Ambulatory Care
  • 10.2. Diagnostic Laboratories
  • 10.3. Hospitals
  • 10.4. Research Institutes
    • 10.4.1. Academic Institutes
    • 10.4.2. Private Research Centers

11. Cancer Diagnostics Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Cancer Diagnostics Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Cancer Diagnostics Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Cancer Diagnostics Market

15. China Cancer Diagnostics Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Abbott Laboratories
  • 16.6. Agilent Technologies, Inc.
  • 16.7. Becton, Dickinson and Company
  • 16.8. Bio-Rad Laboratories, Inc.
  • 16.9. bioMerieux SA
  • 16.10. Canon Medical Systems Corporation
  • 16.11. Danaher Corporation
  • 16.12. Danaher Corporation
  • 16.13. DiaSorin S.p.A.
  • 16.14. F. Hoffmann-La Roche Ltd
  • 16.15. Fujifilm Corporation
  • 16.16. GE HealthCare Technologies Inc.
  • 16.17. Hologic, Inc.
  • 16.18. Illumina, Inc.
  • 16.19. Myriad Genetics, Inc.
  • 16.20. NeoGenomics Laboratories, Inc.
  • 16.21. PerkinElmer, Inc.
  • 16.22. QIAGEN N.V.
  • 16.23. Quest Diagnostics Incorporated
  • 16.24. Siemens Healthineers AG
  • 16.25. Sysmex Corporation
  • 16.26. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CELL SORTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CELL SORTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CELL SORTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MULTIPARAMETER FLOW CYTOMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MULTIPARAMETER FLOW CYTOMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MULTIPARAMETER FLOW CYTOMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CHROMOGENIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CHROMOGENIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CHROMOGENIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY FLUORESCENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY FLUORESCENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY FLUORESCENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PRIVATE RESEARCH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PRIVATE RESEARCH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PRIVATE RESEARCH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 206. GCC CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. GCC CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. GCC CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 209. GCC CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 210. GCC CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 211. GCC CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 212. GCC CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. GCC CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 214. GCC CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 215. GCC CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. GCC CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 239. G7 CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. G7 CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 241. G7 CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 242. G7 CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 243. G7 CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 244. G7 CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 245. G7 CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. G7 CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 247. G7 CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 248. G7 CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. G7 CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 250. NATO CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 251. NATO CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 252. NATO CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 253. NATO CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 254. NATO CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 255. NATO CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 256. NATO CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. NATO CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 258. NATO CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 259. NATO CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. NATO CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 261. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)